Background Belimumab, the first biologic approved for the treatment of systemic lupus
erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE …

Belimumab (Benlysta®) is a fully humanized monoclonal antibody that inhibits B-lymphocyte
stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was …

Objectives To identify factors that predict response to belimumab treatment in the phase 3
BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further …

Objective. To evaluate the use and efficacy of belimumab in academic practices. Belimumab
is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been …

Introduction Belimumab is a recombinant human monoclonal antibody that binds to soluble
B-lymphocyte stimulator and inhibits its biological activity. Since receiving approvals for the …

Objective To evaluate the safety profile of long‐term belimumab therapy combined with
standard therapy for systemic lupus erythematosus (SLE) in patients with active disease …

There have been significant advancements in understanding the immunopathogenesis of
systemic lupus erythematosus. However, the developments in therapeutics have been rather …

Background Belimumab, an anti-B-cell activating factor antibody, is approved for the
treatment of auto-antibody positive systemic lupus erythematosus with a high degree of …

Systemic lupus erythematosus (SLE) has a complex clinical picture, and a number of defects
in the immune system have been described in patients with the disease. Most organs can be …

Introduction The real-world effectiveness of belimumab for systemic lupus erythematosus
(SLE) in six countries was evaluated in the OBSErve program. The aim of this post hoc …